NYSE · LLY
Eli Lilly and Company
$1,415.83+$42.13 (+3.07%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.33% below the high.
Loading market information…
OTC · BIOQ · USD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Bioqual, Inc.’s quoted price sits in the lower half of its reported 52-week range, 22.5% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Bioqual, Inc.’s forward annual dividend is $0.50 per share, paid annual. The forward yield is 1.61% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Bioqual, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Bioqual, Inc. delivers a range of preclinical research solutions, encompassing both in-vivo and in-vitro methodologies, to its diverse clientele of commercial enterprises and government agencies across the United States. Their expertise spans numerous critical health domains, including investigations into COVID-19, AIDS, influenza, RSV infection, and various flaviviruses such as Zika and Dengue. Furthermore, their work extends to malaria, hepatitis, and oncology. The firm's comprehensive laboratory capabilities further include processing biological samples, producing virus stocks, precisely quantifying infectious viral loads, and conducting assays like virus neutralization and hemagglutination inhibition. They also utilize advanced techniques such as quantitative PCR, ELISA for antigen and antibody detection, flow cytometry, lymphocyte proliferation studies, and various other cell-based analytical methods. Moreover, Bioqual furnishes specialized support for studies employing animal research models. Established in 1981, Bioqual, Inc. maintains its primary operational base in Rockville, Maryland.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:57 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,415.83+$42.13 (+3.07%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.33% below the high.
$273.32-$1.88 (-0.68%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 3.08% below the high.
$294.15+$3.36 (+1.16%)
AbbVie Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.54% below the high.
$149.55+$3.22 (+2.2%)
Merck & Co., Inc.’s quoted price sits in the upper half of its reported 52-week range, 4.7% below the high.
$406.64-$4.27 (-1.04%)
UnitedHealth Group Incorporated’s quoted price sits in the upper half of its reported 52-week range, 11.96% below the high.
$697.06-$12.12 (-1.71%)
Thermo Fisher Scientific Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.09% below the high.
$466.11+$5.38 (+1.17%)
Amgen Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.01% below the high.
$170.51+$4.90 (+2.96%)
Gilead Sciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.93% below the high.
